David D. Kim

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.